Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Autor:
Zita Borbényi, Suddhasatta Acharyya, Karen W.L. Yee, Je-Hwan Lee, Massimo Breccia, S. Ide, Árpád Illés, Alan Macwhannell, Carlos Graux, Miklos Egyed, Nancy Zhu, David Valcárcel, James D. Cavenagh, Reinhard Stauder, Huda Salman, Daniel J. DeAngelo, Mikkael A. Sekeres, M. Marker, Oliver G. Ottmann, G. Garcia-Manero, Lucien Gazi, Pierre Fenaux
Publikováno v:
Leukemia
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
Autor:
Eunice S. Wang, Deedra Nicolet, Andrew J. Carroll, A-K Eisfeld, Clara D. Bloomfield, Christopher J. Walker, Shelley Orwick, Jonathan E. Kolitz, Richard Stone, James S. Blachly, A de la Chapelle, John C. Byrd, Karl Kroll, Jessica Kohlschmidt, Krzysztof Mrózek, Bayard L. Powell
Publikováno v:
Leukemia
Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML patients, and are used to denote specific
Autor:
Chiara Milanesi, Chiara Cavalloni, Emanuela Sant'Antonio, Mario Cazzola, Maria C. Renna, Emanuela Boveri, Ilaria Carola Casetti, Vittorio Rosti, Elisa Roncoroni, Daniela Pietra, Elisa Rumi, Elena Fugazza, Cesare Astori, Vittorio Abbonante, C. A. Di Buduo, Francesco Moccia, Marta Bellini, Alessandra Balduini, G Barosi, Virginia Valeria Ferretti
Publikováno v:
Leukemia
A quarter of patients with essential thrombocythemia or primary myelofibrosis carry a driver mutation of CALR, the calreticulin gene. A 52-bp deletion (type 1) and a 5-bp insertion (type 2 mutation) are the most frequent variants. These indels might